Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Jun 26;7(13):e009047.
doi: 10.1161/JAHA.118.009047.

High Burden of 30-Day Readmissions After Acute Venous Thromboembolism in the United States

Affiliations

High Burden of 30-Day Readmissions After Acute Venous Thromboembolism in the United States

Eric A Secemsky et al. J Am Heart Assoc. .

Abstract

Background: Venous thromboembolism (VTE) is the third leading cause of vascular disease and accounts for $10 billion in annual US healthcare costs. The nationwide burden of 30-day readmissions after such events has not been comprehensively assessed.

Methods and results: We analyzed adults ≥18 years of age with hospitalizations associated with acute VTE between January 1, 2010, and December 31, 2014, in the Nationwide Readmissions Database. International Classification of Disease, Ninth Revision, Clinical Modification (ICD-9-CM) codes were used to identify hospitalizations associated with acute pulmonary embolism or deep vein thrombosis. The primary outcome was the rate of unplanned 30-day readmission. Hierarchical logistic regression was used to calculate hospital-specific 30-day risk-standardized readmission rates, a marker of healthcare quality. Among 1 176 335 hospitalizations with acute VTE, in-hospital death occurred in 6.2%. VTE was associated with malignancy in 19.7%, recent surgery in 19.3%, recent trauma in 4.6%, hypercoagulability in 3.3%, and pregnancy in 1.0%. Among survivors to discharge, the 30-day readmission rate was 17.5%, with no significant difference in rates across study years (17.4%-17.7%; P=0.10 for trend). Major predictors of readmission were malignancy (relative risk, 1.49, 95% confidence interval 1.47-1.50), Medicaid insurance (relative risk, 1.48, 95% confidence interval 1.46-1.50), and nonelective index admission (relative risk, 1.31, 95% confidence interval 1.29-1.33). Top causes of readmission included sepsis (9.6%) and procedural complications (8.1%). Median rehospitalization costs were $9781.7 (interquartile range, $5430.7-$18 784.1), and 8.1% died during readmission. The interquartile range in risk-standardized readmission rates was 16.6% to 18.3%, suggesting modest interhospital heterogeneity in readmission risk.

Conclusions: Nearly 1 in 5 patients with acute VTE were readmitted within 30 days. Predictors and causes of readmission were primarily related to patient characteristics and complications from comorbid conditions, whereas healthcare quality had a moderate impact on readmission risk.

Keywords: deep vein thrombosis; pulmonary embolism; readmission; venous thromboembolism.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Displayed is a forest plot with predictors of nonelective 30‐day readmission after acute venous thromboembolism. The strongest predictors included malignancy, nonelective index hospitalization, insurance type (Medicaid and Medicare), acute heart failure exacerbation, and discharge to a short‐term facility. Risk estimates are relative risks with 95% confidence intervals. DVT indicates deep vein thrombosis; PE, pulmonary embolism.
Figure 2
Figure 2
The figure displays the main reasons for 30‐day readmission. The most common cause of readmission was sepsis, followed by procedural complications and issues related to malignancy. DVT indicates deep vein thrombosis.
Figure 3
Figure 3
Frequency of 30‐day risk‐standardized readmission rates across institutions in 2014. Displayed on the X‐axis are the hospital‐specific 30‐day risk‐standardized readmission rates for each hospital included in the study. Displayed on the Y‐axis are the frequencies of hospitals with the specific risk‐standardized readmission rate.

References

    1. Raskob GE, Angchaisuksiri P, Blanco AN, Buller H, Gallus A, Hunt BJ, Hylek EM, Kakkar A, Konstantinides SV, McCumber M. Thrombosis: a major contributor to global disease burden. Arterioscler Thromb Vasc Biol. 2014;34:2363–2371. - PubMed
    1. Bell EJ, Lutsey PL, Basu S, Cushman M, Heckbert SR, Lloyd‐Jones DM, Folsom AR. Lifetime risk of venous thromboembolism in two cohort studies. Am J Med. 2016;129:339.e19–339.e26. - PMC - PubMed
    1. Silverstein MD, Heit JA, Mohr DN, Petterson TM, O'fallon WM, Melton LJ. Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25‐year population‐based study. Arch Intern Med. 1998;158:585–593. - PubMed
    1. Weller WE, Gallagher BK, Cen L, Hannan EL. Readmissions for venous thromboembolism: expanding the definition of patient safety indicators. Jt Comm J Qual Saf. 2004;30:497–504. - PubMed
    1. Grosse SD, Nelson RE, Nyarko KA, Richardson LC, Raskob GE. The economic burden of incident venous thromboembolism in the United States: a review of estimated attributable healthcare costs. Thromb Res. 2016;137:3–10. - PMC - PubMed

Publication types

MeSH terms

LinkOut - more resources